After appeal, East Bay drugmaker snares FDA do-over for dialysis patient drug

A conclusion to the company's rollercoaster journey to win approval of a drug for a subset of chronic kidney disease patients appears closer. But its stock opened down Thursday.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news